PuraStat shows its efficacy in achieving endoscopic haemostasis in postoperative anastomotic ulcers

A new interesting case report highlights the efficacy of PuraStat for achieving endoscopic...

A new prospective observational registry (POPS) in the Middle East has launched in Kuwait

3-D Matrix is pleased to announce that a new prospective observational study (POPS) has started in ...

3-D Matrix Summer Update

3-D Matrix would like to wish you all a wonderful summer and take this opportunity to remind you...

3-D Matrix strengthens its relationship with its distribution partners.

During 3-D Matrix's quarterly European sales meeting, held in Barcelona from the 22nd to the 24th...

A new multicentre randomised controlled trial has started in Germany to evaluate PuraStat efficacy in preventing delayed bleeding after endoscopic resections.

The clinical investigation “Prospective, multicentre randomised controlled trial of the...

A new multicentre study investigating PuraStat efficacy, safety, and ease of use for haemostasis in endonasal surgery (turbinate reduction, septoplasty and FESS).

Bleeding is a common intraoperative and/or post-operative issue in Endoscopic Endonasal Surgery...

Notice regarding the Conclusion of an Agreement Concerning Manufacturing License with FUSO Pharmaceutical Industries, Ltd.

3-D Matrix, Ltd. (headquarters: Chiyoda-ku, Tokyo; President and Representative Director: Jun...

RADA16 use in Plastic surgery (facelift): a pilot study with an optimised application technique

The facelift is one of the most common cosmetic surgeries performed. Although the procedure is...

3-D Matrix keeps aiming in the ENT and Plastic Surgery medical areas with PuraBond

The 3-D Matrix agenda keeps being filled with a selection of events, including those dedicated to...

PuraStat becomes PuraBond for cardiac surgeons in Spain

In conjunction with its participation at the XXVI edition of the Secce’s congress in Oviedo, 3-D...